Thomas Chalopin

8PUBLICATIONS
23CO-AUTHORS
Predictive and prognostic markersGene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 03, 2026
Response profile and long-term outcomes in Cyclin D1-overexpressing multiple myeloma: insights from the CASSIOPEIA trial.

|Oct 24, 2025
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience.

Philippe Moreau, Cyrille Hulin, Alexis Talbot

|Oct 21, 2025
Debulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort study.

Thomas Chalopin, Elise Cellerin, Hélène Demarquette

|Jan 22, 2025
Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial.

Aurore Perrot, Cyrille Touzeau, Jerome Lambert

|Jan 06, 2025
Iberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse.

Cyrille Touzeau, Xavier Leleu, Mourad Tiab

|Apr 30, 2021
No survival improvement in patients with high-risk multiple myeloma harbouring del(17p) and/or t(4;14) over the two past decades.

Thomas Chalopin, Nicolas Vallet, Olivier Theisen

Pageof 2

Frequent Collaborators

5 joint publications

Xavier Leleu

5 joint publications

Jill Corre

4 joint publications

Philippe Moreau

4 joint publications

Cyrille Touzeau